Brought to you by 
Novartis acquires Hexal, Eon Labs for €5.65bn
23 Feb 2005
Executive Summary
Novartis has agreed to acquire two generics companies for €5.65bn ($7.38bn) in cash--67.7% of Eon Labs for €1.3bn and 100% of Hexal AG, Eon's parent company, for €4.35bn. Novartis plans to buy the remainder of Eon via a tender offer of €23.73 per share (a 25% premium to Eon's trading price before the market was affected by take-over speculation).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis acquires Hexal, Eon Labs for €5.65bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice